Medicines for Europe Commentary on the Draft EMA regulatory science strategy 2025

How can your healthcare system support a wider access to Value Added Medicines?

Annual Medicines for Europe and IGBA Conference 2019

Infographic: Value Added Medicines Provide a Wide Range of Different and Important Benefits to Patients, Healthcare Professionals and Healthcare Systems

Case Studies for Value Added Medicines. Unlocking the potential of patient-centric continuous innovation

15th Legal Affairs Conference

18th Regulatory and Scientific Affairs Conference

12th Pharmacovigilance Conference

Do you care about patient access? The SPC manufacturing waiver can help!

Joint pharmaceutical industry statement on the Commission’s proposal for a Regulation on health technology assessment (HTA)